Emerging Agents in the Treatment of Rheumatic Diseases


In this MEDcast episode, Drs. Soloman, Sharobeem, and Mease discuss newer mechanisms of actions and emerging therapies in rheumatic diseases and tools that are becoming available to rheumatologists to practice precision medicine.

To watch the video series component of this episode, click here.

00:00 Welcome and introductions

01:40 Novel therapeutic agents targeting pathophysiology of rheumatic diseases

06:15 IL-17A, IL-17F inhibitor bimekizumab

07:42 Tyk2 inhibitor deucravacitnib in rheumatology

09:50 IL-17A inhibitor izokibep in psoriatic arthritis

11:10 Outcome measures in rheumatic diseases

16:20 Molecular signature response classifier (MSRC) test

19:40 Biosimilars in rheumatology

24:30 Precision medicine in clinical practice

29:30 Role of advanced practice practitioners in rheumatology

Recent Videos
Signs and Symptoms of Connective Tissue Disease
Connective Tissue Disease Brings Dermatology & Rheumatology Together
© 2024 MJH Life Sciences

All rights reserved.